Consensus $2.49. Edwards Lifesciences (EW) announced that the U.S. Federal Trade Commission moved to block the company’s proposed acquisition of JenaValve Technology. In light of FTC’s action, Edwards is revising its full-year 2025 financial guidance. “There is no impact to revenue guidance. The company is increasing its adjusted Earnings Per Share guidance for the full year to the high-end of $2.45-$2.55, up from the high-end of $2.40-$2.50. There will be minimal impact to the company’s Q3 adjusted EPS guidance,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards to pursue regulatory approval after FTC action to block JenaValve deal
- Edwards Lifesciences’ SAPIEN 3 Valve Study: A Real-World Evaluation
- Edwards Lifesciences’ PASCAL System: A Promising Update in Tricuspid Valve Repair
- Edwards Lifesciences’ SAPIEN 3 Study: A Market Game-Changer?
- Edwards Lifesciences’ Pivotal Trial: A Game-Changer for Tricuspid Valve Repair?